Objective:
To evaluate the effectiveness of the Calibreye Titratable Glaucoma Therapy Surgical System in managing intraocular pressure (IOP) postoperatively, specifically focusing on its adjustable resistance mechanism.
Key Findings:
- At 12 months, 81% of implanted eyes were set at the device's lowest resistance.
- Mean IOP was reduced to 14.5±4.6 mmHg, a 35% reduction from baseline.
- 93.5% of patients were medication-free or using the same or fewer medications than at baseline.
- No intraprocedural adverse events were reported, and no cases required bleb needling.
- When resistance was increased in 7 eyes, mean IOP rose by 1.9±1.3 mmHg, demonstrating bidirectional control.
Interpretation:
The adjustable resistance mechanism of the Calibreye system provides comparable IOP and medication reductions to existing drainage devices while allowing for postoperative customization, potentially mitigating early hypotony and enabling individualized pressure control.
Limitations:
- The study was nonrandomized and open-label, which may introduce bias.
- Longer-term follow-up is needed to assess the durability of outcomes.
Conclusion:
The Calibreye system offers a promising new approach to glaucoma management, allowing for tailored postoperative pressure control.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.